Avaleht › Müeloom › Connecticut › New Haven
Müeloom kliinilised uuringud linnas New Haven, CT
14 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas New Haven ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
VärbamineFaas 3
- Research Site, New Haven
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
VärbamineFaas 2
- Yale University School Of Medicine, New Haven
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- Yale Cancer Center, New Haven
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
VärbamineFaas 3
- Yale New Haven Hospital, New Haven
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi kaugusel
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi kaugusel
- ja veel 1
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
VärbamineFaas 1/2
- Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
VärbamineFaas 3
- Yale University, New Haven
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1/2
- Yale New Haven Hospital-Smilow Cancer Center, New Haven
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
VärbamineFaas 3
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi kaugusel
- ja veel 3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
VärbamineFaas 3
- Research Site, New Haven
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
VärbamineFaas 3
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi kaugusel
- ja veel 2
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
VärbamineFaas 3
- Yale New Haven Hospital, New Haven
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
VärbamineFaas 2
- Yale University, New Haven
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- Yale Cancer Center, New Haven
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas New Haven
- Mitteväikerakuline kopsuvähk41 uuringut
- Rinnavähk37 uuringut
- Vähk (kõik liigid)33 uuringut
- Metastaatiline vähk23 uuringut
- Kopsuvähk22 uuringut
- Pea ja kaela lameepiteeli kartsinoom22 uuringut
- Munasarjavähk21 uuringut
- Käär- ja pärasoolevähk20 uuringut
- Eesnäärmevähk20 uuringut
- Opioidide üleannustamine18 uuringut
- Alkoholitarbimise häire (AUD)17 uuringut
- Äge müeloidne leukeemia17 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.